Cancers of kidney (mostly renal cell carcinoma) appear to require VHL mutation along with two other genetic alterations that may include EGFR mutation, overexpression of genes associated with cellular adhesion molecules (e.g. E-cadherin) and matrix regulatory proteins (e.g. MMPs, bFGF, VEGF) or rarely p53 [20]. This evidence concerns the gene TP53 and kidney cancer.